Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E48.12 EPS (ttm)7.71 Insider Own1.40% Shs Outstand105.51M Perf Week3.14%
Market Cap39.16B Forward P/E23.54 EPS next Y15.77 Insider Trans-0.48% Shs Float77.35M Perf Month2.14%
Income895.50M PEG2.58 EPS next Q3.12 Inst Own71.30% Short Float2.61% Perf Quarter-11.64%
Sales4.86B P/S8.06 EPS this Y39.50% Inst Trans-0.41% Short Ratio2.11 Perf Half Y-9.66%
Book/sh42.33 P/B8.77 EPS next Y18.98% ROA13.80% Target Price434.68 Perf Year-6.03%
Cash/sh9.84 P/C37.70 EPS next 5Y18.68% ROE21.30% 52W Range325.35 - 452.96 Perf YTD1.11%
Dividend- P/FCF40.73 EPS past 5Y38.80% ROI18.20% 52W High-18.05% Beta1.39
Dividend %- Quick Ratio2.30 Sales past 5Y61.30% Gross Margin93.80% 52W Low14.09% ATR10.50
Employees5400 Current Ratio2.60 Sales Q/Q11.70% Oper. Margin27.40% RSI (14)54.22 Volatility2.77% 2.77%
OptionableYes Debt/Eq0.11 EPS Q/Q63.00% Profit Margin18.40% Rel Volume0.81 Prev Close373.02
ShortableYes LT Debt/Eq0.08 EarningsFeb 09 BMO Payout0.00% Avg Volume957.72K Price371.18
Recom2.20 SMA203.25% SMA501.11% SMA200-3.10% Volume775,547 Change-0.49%
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Feb-16-17 09:20AM  Why Amgen's Becoming One of My Top Dividend Stocks to Buy at Motley Fool
08:17AM  Regeneron Pharma downgraded by Goldman
07:04AM  Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
Feb-14-17 05:12PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : February 14, 2017
08:33AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : February 14, 2017
07:54AM  These 25 Companies Could Get a Big Profit Boost From a Little Known Part of Trump's Tax Reform
Feb-13-17 02:25PM  Regeneron: It's All Riding On Dupixent at
10:49AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017
09:30AM  Regeneron Announces Upcoming 2017 Investor Conference Presentations PR Newswire
07:45AM  Early movers: AAPL, DD, TEVA, QSR, FDC, HAS, JCP & more at CNBC
Feb-10-17 02:50PM  3 Beaten-Down Stocks Ready to Bounce Back at Motley Fool
09:17AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017
08:15AM  Blog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial Accesswire
05:54AM  [$$] 12 Stocks to Benefit Most From the House Tax Plan at
Feb-09-17 06:00PM  Edited Transcript of REGN earnings conference call or presentation 9-Feb-17 1:30pm GMT
04:56PM  Regeneron Defies Light Q4 Sales, Eylea Outlook On Amgen-Rivaling LDL Win
04:26PM  Regeneron says it is being investigated by the US Attorney's Office over patient assistance nonprofit at MarketWatch
02:01PM  Regeneron: Whiplash! at
01:14PM  [$$] Regeneron Is Primed for a Second Act at The Wall Street Journal
01:11PM  Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales at Insider Monkey
11:09AM  Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
10:56AM  Judge Lifts Ban on Amgen Cholesterol Drug Rival at Investopedia
10:03AM  Regeneron (REGN) Q4 Earnings Misses Estimates
09:05AM  Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
08:33AM  Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now
08:31AM  Regeneron forecasts 2017 U.S. Eylea sales growth below estimates
08:17AM  A Heart-Stopping Patent Injunction Stay For Sanofi at Forbes
07:51AM  Early movers: KO, TWTR, VIAB, CVS, YUM, RAI, & more at CNBC
07:17AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:17AM  Regeneron misses Street 4Q forecasts
07:07AM  Q4 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:37AM  Regeneron revenue rises 11.7 pct on Eylea eye drug
06:30AM  Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results PR Newswire
Feb-08-17 07:02PM  [$$] Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug at The Wall Street Journal
05:46PM  Sanofi: Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process GlobeNewswire
05:33PM  Regeneron, Sanofi Temporarily Stave Off Ban Of Amgen-Rivaling LDL-Buster
05:30PM  Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process PR Newswire
04:49PM  Federal appeals court decision will keep Regeneron/Sanofi drug at center of patent dispute on market, for now at MarketWatch
04:39PM  Judge: Regeneron can keep selling cholesterol drug
04:14PM  Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
08:08AM  [$$] Sanofi Seeks Cure for FDA Concerns at French Factory at The Wall Street Journal
07:27AM  Earnings Preview: What To Expect From Regeneron On Thursday at Forbes
03:25AM  Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A
Feb-07-17 06:30AM  Regeneron to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2017 PR Newswire
06:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
05:43AM  [$$] Where a Go-Anywhere Fund Is Finding Growth at
Feb-03-17 04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
Feb-02-17 04:58PM  Amgen Crushes Q4 Views, But Sees Light 2017 Sales; Repatha Tops CV Study
04:27PM  Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study
Feb-01-17 07:50AM  SanofiRegeneron Sarilumab Approved in Canada for Arthritis
01:03AM  Sanofi and Regeneron Announce First Approval of Kevzara(TM) (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada GlobeNewswire
01:00AM  Regeneron and Sanofi Announce First Approval of Kevzara (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada PR Newswire
Jan-31-17 08:35AM  Merrill Lynch Says 5 Companies Could Benefit Huge From Trump Tax Plan 24/7 Wall St.
07:00AM  Tony Coles, M.D., Elected to Regeneron Board of Directors PR Newswire
Jan-30-17 04:18PM  Regeneron, Sanofi Could Appease LDL-Frustrated Buyers On Eczema Drug
11:30AM  11 Highest Paid CEOs In The World at Insider Monkey
Jan-26-17 01:21PM  Biotech ETFs: Is It Time To Buy? at
12:27PM  Manning & Napier's Top 3 New Holdings
07:01AM  3 Top Biotech Stocks You Can Still Buy With the Dow at 20,000 at Motley Fool
Jan-24-17 03:35PM  Is Amgens Cardiovascular Segment Still a Growth Opportunity?
12:00PM  Forty of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists PR Newswire
08:04AM  On Experiencing The Failure Of A Billion-Dollar Clinical Program at Forbes
Jan-23-17 02:16PM  Top Biotech Stocks to Buy in 2017 at Motley Fool
12:00PM  Failed Mergers Cast Shadow on Sanofi's Future at Investopedia
Jan-20-17 08:19AM  Regeneron Pharmaceuticals Could Be Ready to Rebound
06:29AM  Here are the stock markets biggest winners and losers during Obamas presidency at MarketWatch
Jan-19-17 12:55PM  These Insiders Are Still Finding Some Good Value in the Stock Market
11:11AM  A Green Light on Bayer
Jan-18-17 09:26AM  5 Biotech Stocks You'll Want to Watch in the 1st Quarter at Motley Fool
Jan-17-17 04:43PM  Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad
08:28AM  Key FDA Events to Watch Out for in Q1
Jan-15-17 07:10AM  Why Regeneron Pharmaceuticals, Inc. Stock Slipped 32.4% in 2016 at Motley Fool
Jan-13-17 04:32PM  Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink
Jan-12-17 12:04PM  Regeneron, Sanofi's Drug Manufacturing Plant Cleared at Investopedia
11:56AM  [$$] Sanofi confident it can overturn Praluent patent ruling at Financial Times
10:05AM  Merrill Lynch Has 4 Red-Hot Stocks to Buy With Up to 75% Upside Potential
Jan-11-17 01:26PM  Trump's Comments Are Big Pharma's Nightmare at Forbes
12:26PM  Trump's Comments Are Big Pharma's Nightmare
Jan-10-17 12:59PM  Todd Hagopian's Top Biotech Takeover Targets For 2017 at Forbes +5.05%
11:26AM  Regeneron CEO: The industry doesn't put patients first
09:30AM  The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals
08:53AM  2 Top Stocks in Biotech at Motley Fool
08:51AM  Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit
Jan-09-17 08:48PM  Regeneron CEO says Amgen not putting patients first in patent dispute Reuters
05:23PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
01:30PM  Morgan Stanley Cuts Regeneron Target On Praluent Patent Worries at
10:10AM  Company News for January 09, 2017
09:00AM  The FDA Approved Fewer Drugs in 2016: Here's Why
08:15AM  Blog Coverage Amgen's Legal Victory Blocks Rivals Sanofi and Regeneron from Selling their Cholesterol Drug in the US Accesswire
Jan-08-17 11:54PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
02:02PM  Why Biotech Titans Are Clashing Over Cholesterol at Motley Fool
Jan-07-17 11:13AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer at Motley Fool
10:47AM  Judges unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake at MarketWatch
Jan-06-17 08:09PM  Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17) -5.84%
06:41PM  Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today at Motley Fool
06:35PM  The Biggest Loser: Regeneron Sinks 5.8% at
04:56PM  [$$] Amgen Patent Win Boosts Odds of a Stock Comeback at
04:42PM  Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication
04:22PM  Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products; and collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize fasinumab, an investigational NGF antibody in Phase III clinical development for osteoarthritis pain and in Phase II development for chronic low back pain. The company also has a strategic collaboration, option, and license agreement with Ocular Therapeutix for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other retinal diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM